Project description
Enhancing prediction of severe adverse effects early in the drug development pipeline
Around 9 of every 10 drug candidates fail to win approval. Drugs can often progress into phase III clinical trials - trials with patients - before some rare but potentially lethal side effects become apparent. This late-stage discovery has significant consequences for the time and cost of drug development. Safety pharmacology is a rapidly developing discipline that seeks to predict whether a drug is likely to be found unsafe if administered to human beings. INSPIRE plans to advance the field of safety pharmacology with a focus on cardiovascular events. Bringing together interrelated expertise including academics, pharmaceutical companies, hospitals, and regulators, the team is fostering innovation among early stage researchers to detect and minimise cardiovascular adverse events early in the pipeline.
Fields of science
Programme(s)
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
2000 Antwerpen
Belgium
See on map
Participants (10)
6200 MD Maastricht
See on map
NG7 2RD Nottingham
See on map
78153 Le Chesnay Cedex
See on map
Participation ended
2333 BD Leiden
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1070 Bruxelles
See on map
78230 LE P Le Pecq
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
61352 Bad Homburg Vor Der Hohe
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
55218 Ingelheim
See on map
7610001 Rehovot
See on map
2333 BD Leiden
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.